Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was enjoyable, because that startling routine of deadlines and meetings and what-not has now returned. But you knew this was coming, yes? Avoiding the future is a difficult thing. So please join us as we hoist our ritualistic cup of stimulation and attack the ever-growing to-do list. Meanwhile, here are some tidbits to get you started. Hope you conquer the world today, and do keep us in mind if you hear anything interesting. …

Sanofi (SNY) and GlaxoSmithKline (GSK) announced positive results from a Phase 2 clinical trial of their joint Covid-19 vaccine, saying it generated strong levels of neutralizing antibodies in recipients across all ages studied, and that a large international Phase 3 trial will begin in coming weeks, STAT says. The duo is far behind in the effort to produce a vaccine and lock down markets for their product, having suffered a setback in a Phase 1/2 trial last year. But with global vaccine supplies falling short, they still believe there is a place for their shot.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.